Prof. Jean-Yves Blay, MD, PhD
Professor of Medicine
Université Claude Bernard
Lyon, France
Scientific Director
Canceropole Lyon Rhône Alpes
Professor of Medicine
Université Claude Bernard
Lyon, France
Scientific Director
Canceropole Lyon Rhône Alpes
Related Videos
Can you describe a specific patient example and tumor type where whole exome sequencing (WES) with NGS generated a safe and effective treatment option that would not have emerged empirically without NGS?
Based on the evidence available, how should we be integrating and incorporating ctDNA profiling — liquid biopsies — with tissue-based whole exome NGS, including longitudinal biopsies?
When evaluating the receptivity of a patient and tumor to immune checkpoint blockade, why are total mutational burden and genomic stability — chromosome deletions and additions — as important as expression of the IC receptor?
What do you see as the significance of the FDA approval of PD-1 inhibitors for all tumors with MSI? What other canonical driver mutations — BRAF, ALK, and others — of similar significance do you see coming down the road?
What is your detailed analysis of the results from ProfiLER Study evaluating NGS-based, whole exome molecular profiling in patients with advanced or refractory cancer?